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Abstract
It has been demonstrated that the p53 pathway plays an important role in HIV-1 infection. Previous
work from our lab has established a model demonstrating how p53 could become inactivated in
HIV-1 infected cells through binding to Tat. Subsequently, p53 was inactivated and lost its ability to
transactivate its downstream target gene p21/waf1. P21/waf1 is a well-known cdk inhibitor (CKI)
that can lead to cell cycle arrest upon DNA damage. Most recently, the p21/waf1 function was
further investigated as a molecular barrier for HIV-1 infection of stem cells. Therefore, we reason
that the restoration of the p53 and p21/waf1 pathways could be a possible theraputical arsenal for
combating HIV-1 infection. In this current study, we show that a small chemical molecule, 9-
aminoacridine (9AA) at low concentrations, could efficiently reactivate p53 pathway and thereby
restoring the p21/waf1 function. Further, we show that the 9AA could significantly inhibit virus
replication in activated PBMCs, likely through a mechanism of inhibiting the viral replication
machinery. A mechanism study reveals that the phosphorylated p53ser15 may be dissociated from
binding to HIV-1 Tat protein, thereby activating the p21/waf1 gene. Finally, we also show that the
9AA-activated p21/waf1 is recruited to HIV-1 preintegration complex, through a mechanism yet to
be elucidated.
Introduction
Amid the availability of current diverse classes of anti-HIV
reagents such as reverse transcriptase (RT), protease (PR)
and fusion inhibitors, the development of inhibitors tar-
geting another important HIV enzyme IN (integrase) has
stimulated great interests in that there is an absence of cel-
lular homologues of IN in cells. A number of HIV-1 IN
inhibitors have been identified and few have been clini-
cally examined including GS-9137 [1-3] and MK-0518
[4]. Recently, increasing evidence has indicated that small
chemical molecules, such as nucleoside antiretroviral rea-
gents, may be advantageous over other antiviral reagents,
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binding properties [5-7]. So far few detailed studies have
been carried out in investigating the role of these small
chemical molecules involved in the signaling pathway(s)
of HIV-infected cells. However, exploring whether there
are novel small chemical molecules or small peptides that
can reactivate important cell signaling pathways (i.e., p53
and/or p21/waf1) that are normally inactivated in HIV-1
infected cells may help to identify important mechanisms
that play key roles in HIV-1 infection and provide a new
set of preventive and/or therapeutic drug-targets.
P53 pathway has been revealed to play an important role
in HIV-1 infection [8,9]. It was also shown that p53 is
involved in apoptosis, where cell death can be induced by
HIV-1 envelope through mTOR-mediated phosphoryla-
tion of p53 on Ser15 [10,11]. Our previous work estab-
lished a model where p53 was inactivated in HIV-1
infected cells through binding to Tat protein. Subse-
quently, p53 was inactivated and lost its ability to transac-
tivate its downstream target gene p21/waf1 [12]. The
interplay between p53 and HIV-1 Tat has also been exten-
sively studied. An RGD-containing domain of Tat protein,
Tat-(65–80), was found to be important in regulating the
proliferative functions of a variety of cell lines, including
a human adenocarcinoma cell line, A549. The p53 activity
was greatly reduced when cells were treated with Tat-(65–
80) [13]. Tat was also shown to efficiently inhibit the tran-
scription of p53 both in vivo and in vitro. The downregula-
tion of p53 by Tat may be important in the establishment
of productive viral infection in cells and also may be
involved in the development of AIDS-related malignan-
cies [14].
The regulation of the p53 and p21/waf1 pathways by HIV-
1 infection has become a point of interest. Previous stud-
ies have shown that the effects of p21/waf1 are highly cell-
type specific in HIV-1 infection. In macrophages, HIV-1
infection resulted in an increased expression of p21/waf1
[15]. Repression of HIV-1 replication was observed when
p21/waf1 expression was inhibited by small molecules
like compound CDDO (2-Cyano-3, 12-dioxooleana-1, 9-
dien-28-oic acid) [16,17]. This phenomenon was differ-
ent from that of p21/waf1 in HIV-1 infection in T lym-
phocytes, where HIV-1 infection reduced the expression
of p21/waf1 [12]. It also differs in stem cells, where silenc-
ing p21/waf1 expression by siRNA increased the viral rep-
lication [18]. Therefore, we reasoned that it is possible to
inhibit the HIV-1 infection and viral replication through
the restoration of p53 and p21/waf1 pathways using small
chemical molecules or small peptides. More recently, the
p21/waf1 function was investigated as a molecular barrier
for HIV-1 infection in stem cells [18]. Hematopoietic stem
cells were previously demonstrated to be highly resistant
to HIV-1 infection [19-21]. In the study carried by Zhang
J et al, the cdk inhibitor p21/waf1 was revealed to restrict
HIV-1 infection in primitive hematopoietic cells. By
knockdown of the endogenous p21/waf1 level using siR-
NAs, the stem cells became highly susceptible to HIV-1
infection. Further, it was shown that the effect of p21/
waf1 is specific; silencing other p21/waf1 related proteins,
p27 and p18 had no effect on HIV-1 infection. Finally, the
authors demonstrated a novel mechanism in which the
anti-HIV effect of p21/waf1 was the result of its interac-
tion with HIV-1 preintegration complex (PIC). Therefore,
p21/waf1 was suggested to be a possible restriction factor,
similar in function to the TRIM5 and APOBEC3G genes
[22-26]. Similarly, our previous work has shown that
high-titer infection of HIV-1 in T lymphocytes resulted in
a loss of the endogenous p21/waf1 [12], further demon-
strating the importance of p21/waf1 in HIV-1 biology.
In this report, we show that a small chemical molecule
9AA can efficiently reactivate the p53 pathway in HIV-1
infected cells, and accordingly transactivates its down-
stream gene p21/waf1, a gene that has a potential role in
inhibiting viral replication. We have also observed that
the effect of 9AA on HIV-1 viral replication and virus DNA
integration in HIV-1 infected cells is due to the association
of 9AA-induced p21/waf1 with HIV-1 preintegration com-
plex (PIC). The implication of these findings will be dis-
cussed below.
Results
Drug 9AA reactivates the p53 and p21/waf1 pathways in 
HIV-1 infected cells
We have previously reported that in HIV-1 infected T-cells,
p53 was inactivated through binding to HIV-1 Tat protein
and the expression of p21/waf1 was nearly completely
inhibited as a consequence of the inactivation of p53 [12].
Small molecules, such as leptomycin B, actinomycin D,
and 9AA (9-aminoacridine), were demonstrated to be
able to efficiently reactivate p53 in some cancer cell lines
[27-29]. Therefore, we reasoned that restoration of the
p53 function may provide a new way to combat virus
infection where this pathway is normally impaired or
sequestered [30-32]. In this study, we specifically used
9AA and tested whether it could efficiently restore the
functions of p53 and p21/waf1 in HIV-1 infected cells.
We initially started our experiments by using infected and
uninfected matched latent cell lines. We used ACH2 and
CEM as our model cells to study whether p53 could be
reactivated with drug 9AA. We therefore treated both cell
types with a titration of 9AA (0.0 to 5.0 uM). Results in
Figure 1A demonstrate that uninfected CEM cells when
treated with 9AA can show activation of overall p53 levels.
The highest concentration of p53 levels was seen at 2.5
uM of 9AA (Figure 1A, lane 4). Also, a gradual increase of
phosphorylated p53 was seen in these cells. The phospho-Page 2 of 9
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DNA-binding to promoters such as p21/waf1. P21/waf1
has been shown extensively to regulate cell cycle check-
point and apoptosis of many cell types. Further Western
blots of p21/waf1 showed that it also was up-regulated by
9AA at 2.5 uM concentration (Figure 1A, lane 4). No
change in actin levels were seen in any of the drug concen-
trations. Next, we used ACH2 cells in treating with 9AA
(Figure 1B) and found that its p53 phosphorylation pat-
tern and p21/waf1 expression was distinctly different
from uninfected cells. For instance, although there was a
small difference in the overall p53 levels as compared to
uninfected cells, the serine 15 phosphorylation pattern
was distinctly different where a gradual increase was seen
up to 5.0 uM of 9AA (Figure 1B, lane 5). Also, the p21/
waf1 increased levels started at 0.5 uM and peaked at 1.0
uM (Figure 1B, lanes 2 and 3) of 9AA and almost com-
pletely gone at 5.0 uM (Figure 1B, lane 5). Therefore, the
pattern of p53 phosphorylation and p21/waf1 induction
in infected cells is distinctly different from uninfected
cells. Again, no difference in actin levels was seen in these
cells. We next used a peptide (p44) that is known to acti-
vate p53 phosphorylation and induce p21/waf1 in a cdc2-
dependent manner [33]. Quite surprisingly, we found
that phosphorylation of p53 at serine 15 and induction of
p21/waf1 occurred mainly in uninfected but not infected
9AA activates phosphorylation of p53 at Ser15Figure 1
9AA activates phosphorylation of p53 at Ser15. CEM and ACH2 cells were treated with drug 9AA, P44 peptide or 
DMSO as mock control, respectively. Cells were harvested 24 hrs after treatment. Cells were then lysed and subjected to 
western blot for p53, p53ser15 and p21/waf1 (anti-p53, anti-p53 ser15 from Cell Signaling, anti-p21/waf1 from Santa Cruz Bio-
technology). (A) CEM cells, uninfected cells. (B) ACH2 cells, HIV-1 infected cells. (C) ACH2 cells were treated with 9AA at a 
concentration of 2.5 uM. Cells were collected at different time points and then subjected to western blot for detection of the 
phosphorylation of p53ser 15. Actin was used as a loading control.Page 3 of 9
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infected and uninfected cells may be quite distinct and
may have altered function. It is possible that molecules
such as DNA-PK and ATM may be altered by HIV-1 infec-
tion and therefore phosphorylation of its downstream
molecules such as p53. Finally, we asked if p53 phospho-
rylation could be induced in a time-dependent manner.
We added 9AA to ACH2 cells and Western blotted for
phosphorylated p53 and actin. Results indicated that an
increase in p53 phosphorylation is time-dependent and
can be best seen at 48 hours post-treatment (Fig 1C). Col-
lectively, these results indicate that p21/waf1 can be acti-
vated in infected cells (IC50 of ~0.25 uM) and at a higher
concentration (IC50 of ~1.25 uM) in uninfected cells.
Effect of increased p21/waf1 in infected and uninfected 
cells
We have previously shown that drugs or peptides that
increase levels of p21/waf1 result in down-regulation of
cdk2/cyclin E kinase activity [34]. To determine the in vivo
binding and the kinase activity of cdk2/cyclin E to p21/
waf1, we treated both CEM and ACH2 cells with various
concentrations of 9AA (0.1, 0.5, 1.0 uM). We treated these
cells for 24 hours and subsequently lysed and used the
extract for immunoprecipitation (IP) with anti-cyclin E
antibody. The rationale here is that if p21/waf1 is pro-
duced after drug treatment, it could subsequently complex
with cdk2/cyclin E decreasing its kinase activity. Cyclin E
IPs were used for in vitro kinase activity assay using histone
H1 as substrate. Results in Figure 2A indicate that kinase
activity in both cell types was nearly identical as seen in
lane 2. Cells treated with increasing concentration of 9AA
showed that cdk2/cyclin E activity was dramatically
reduced in HIV-1 infected cells at 0.1 uM (Figure 2A, lane
3). However, a dramatic decrease of kinase activity was
seen in uninfected cells at 1.0 uM (Figure 2A, lane 5).
Beads alone control did not bring down cdk2/cyclin E or
any other kinase to phosphorylate the histone H1 (Figure
2A, lane 1, negative control). Importantly, cdk2 levels
were not changed upon the treatment at different concen-
trations of 9AA both in ACH2 and CEM (Fig 2B). Collec-
tively these data indicate that an increase in p21/waf1 in
infected cells at low concentrations was capable of seques-
tering cdk2/cyclin E activity.
Effect of 9AA in PBMC infected cells
To detect whether 9AA could indeed function as an inhib-
itor of HIV-1, we utilized a PBMC infection in vitro. PHA
and IL2 stimulated PBMCs were infected with NL4-3 virus
at an MOI of 1.0. Cells were subsequently treated with
9AA at various concentrations including 0.1, 0.5, and 1.0
uM. Cells were maintained up to 18 days in complete
media in the presence of IL2. Subsequently supernatants
that were collected at days 0, 6, 12, and 18 were assayed
for the presence of RT. Results are shown in Figure 3.
Panel A indicates that viral infection can effectively be
blocked at 0.5 uM although 0.1 uM had ~30–40% inhib-
itory effect. Therefore, the IC50 is at ~0.25 uM for these
PBMC infected cells. More importantly, viability assays of
PBMC infected cells showed no difference as compared to
infected alone or uninfected cells (Figure 3B). Results with
1.0 uM treatment of PBMCs showed a similar pattern of
overall cell death when compared to uninfected cells. Col-
lectively these data indicate that low concentration of 9AA
that is not toxic to primary cells can effectively inhibit
HIV-1 replication in vitro.
Effect of phosphorylation of serine 15 p53 on Tat binding
We have previously shown that unmodified Tat binds
directly to p53 [12]. This is in agreement with a number
of other publications that showed similar Tat p53 binding
[12,13,35-39]. We now asked whether drug treatment
which results in phosphorylation of p53 could still show
binding to Tat. Therefore we transfected ACH2 cells with
a Flag-Tat plasmid and looked for the presence of Flag-Tat
9AA-induced inhibitory effects on cdk2/cyclin E activity in infected and u infected cellsFigure 2
9AA-induced inhibitory effects on cdk2/cyclin E activ-
ity in infected and uninfected cells. (A) ACH2 and CEM 
cells were treated with various concentrations of 9AA (0.1, 
0.5, 1.0 uM) for 24 hrs. Cells were harvested and lysed for 
immunoprecipitation (IP) with α-Cyc E ab followed by kinase 
assays. Histone H1 was used as substrate and was added to 
each reaction tube along with (γ-32P) ATP (3000 Ci/mmol). 
Reactions were incubated at 37°C for 30 minutes and 
stopped by the addition Laemmli buffer. The samples were 
then separated on a 4–20% Tris-Glycine gel. The gel was 
dried and exposed to a PhosphorImager cassette and ana-
lyzed utilizing Molecular Dynamic's ImageQuant Software. (B) 
The lysates from (A) were subjected to western blot to eval-
uate the levels of cdk2 in samples treated with 9AA at differ-
ent concentrations (0, 0.1, 0.5, 1.0 uM).Page 4 of 9
(page number not for citation purposes)
Virology Journal 2008, 5:41 http://www.virologyj.com/content/5/1/41and phosphorylated p53 in treated and untreated cells.
Results in Figure 4A show that Flag-Tat and phospho p53
could be detected before drug treatment. Importantly,
9AA treatment of these cells did not alter the expression
level of Flag-Tat but greatly increased serine 15 p53 levels.
We next immunoprecipitated serine 15 p53 and asked if
Tat was present in that complex after drug treatment.
Results in panel B show that serine 15 phosphorylated
p53 has been dissociated away from Tat and therefore
may now be free to bind to endogenous promoters such
as p21/waf1. In contrast, Tat was found to be associated
with the p53 when the same lysates were incubated with
anti-p53, which is in agreement with our previous work
that p53 is inactivated though binding to HIV-1 Tat pro-
tein [12]. Collectively these results indicate that phospho-
rylation of p53 affects its release from Tat and its DNA-
binding activity and ultimately induce gene expression on
promoters such as p21/waf1.
Drug 9AA induces p21/waf1 and its recruitment into pre-
integration (PIC) complex
A recent publication by Zhang J. et al [18] has shown that
p21/waf1 is a significant barrier of HIV-1 replication in
stem cells. These investigators showed that the addition of
siRNA against p21/waf1 (which was normally present at
high levels) in stem cells allowed active replication of
HIV-1 in these cells. They also suggested that the p21/
waf1 could be complexed with the HIV-1 PIC complex
therefore inhibiting the integration of HIV-1 DNA into the
chromosome. Inspired by their work, we asked if p21/
waf1 levels induced by 9AA could also bind to pre-integra-
tion complex (matrix protein) in our latent cells. There-
fore, ACH2 cells were treated with 9AA and subsequently
immunoprecipitated with anti-matrix protein. Results in
Figure 5A show that p21/waf1 was indeed associated with
matrix protein in these cells after 9AA treatment. Anti-RT
(Reverse Transcriptase) immunoprecipitation was
included in this experiment. We found that p21/waf1 was
not present in the anti-RT immunoprecipitated complex,
which demonstrates that p21/waf1 is specifically associ-
ated with HIV-1 MA (Figure 5B). Collectively these data
indicate that p21/waf1 may indeed bind to pre-integra-
tion complex provided that cells are first treated with 9AA
prior to integration, expanding the role of p21/waf1 mol-
ecule not only in inhibiting integration but also transcrip-
tion as previously shown [12].
9AA-treatment involved in post-reverse transcriptional 
processes of HIV-1 infection
To further explore the mechanism of the antiviral action
of 9AA, we designed experiments to examine whether 9AA
affects the reverse transcriptional process and/or post-
reverse transcriptional process. To this end, CEM cells
were infected with HIV-1 for 6 hrs. The infected cells were
then washed with PBS and cultured with complete
medium containing 9AA (1.0 uM) or DMSO as mock con-
trol. From our analysis of the viral copies by QPCR, we
found that 9AA did not affect the entry step of HIV-1,
which was evident by the fact that viral copies were
observed in the HIV-1 infected/+9AA-treated samples at
the 24 hrs time point. However, samples that were col-
lected after 48 and 72 hrs, demonstrated a significant
9AA inhibits HIV-1 viral replication in PBMCsFigure 3
9AA inhibits HIV-1 viral replication in PBMCs. Phytohemagglutinin-activated PBMCs were kept in culture for 2 days 
prior to infection. Isolation and treatment of PBMCs were performed by following the guidelines of the Centers for Disease 
Control. Approximately 5 × 106 PBMCs were infected with pNL4 (MOI: 1.0). 9AA treatment (0, 0.1, 0.5 and 1.0 uM) was per-
formed immediately after the addition of fresh medium. (A) Samples were collected every 6th day and stored at -20°C for RT 
assays. (B) Cells were also counted (~100/date) for viability using trypan blue staining.Page 5 of 9
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treated samples as compared to HIV-1/+DMSO-treated
sample (Table 1). Collectively, these results indicated that
the drug 9AA does not affect the entry step of virus;
instead, 9AA may also affect the steps after reverse tran-
scription, mostly probably the integration step.
Discussion
P53 was previously shown to be inactivated by HIV-1
infection in T-cells, and consequently downregulates the
expression of its target gene p21/waf1 [12]. In this study,
we demonstrated that the function of p53 and p21/waf1
pathways could be restored by using a small chemical
molecule 9-aminoacridine (9AA) (Figure 1). Very interest-
ingly, 9AA was shown to differentially trigger the activa-
tion of p53 in HIV-1 infected and uninfected cells (Figure
1). P53 is present at low levels under unperturbed condi-
tions, but it becomes rapidly activated and stabilized
upon induction by a number of stimuli, including the use
of reagents that cause DNA damage [40-45]. Phosphoryla-
tion plays a critical role in the activation and stabilization
of p53. Of particular interest is the phosphorylation of
ser15, which is generally considered to be activated in
response to different stress signals [46-50]. The p53 path-
way has been demonstrated to play a key role in HIV-1
infection [8,9]. Previous work in our lab has established a
model demonstrating how p53 could become inactivated
in HIV-1 infected cells through binding to Tat. P53 was
inactivated and lost its ability to transactivate its down-
stream target gene p21/waf1 [12]. In our current study, we
show that the 9AA-triggered phosphorylated p53ser15
does not interact with HIV-1 Tat protein. One possible
explanation may be that the p53ser15 is located in the
core pocket domain which is required for the p53-Tat
interaction, while the phosphorylation of ser15 greatly
reduces the binding affinity to Tat protein.
In the current study we propose that it is feasible to reduce
the HIV-1 infection and viral replication through the res-
toration of p53 and p21/waf1 pathways by using small
chemical molecules or small peptides. When HIV-1
PBMCs were treated with 9AA at a concentration-depend-
ent manner (0, 0.01, 0.5, 1.0 uM), the viral replication
was significantly inhibited at 0.5 uM (Figure 3A), while
the cell growth was not greatly affected (Figure 3B). Fur-
ther, we performed an in vitro kinase assay with another
HIV-1 positive cell line ACH2 treated with 9AA. We
immunoprecipited cdk2/cycle E complex from the drug
treated and untreated samples and the results show that
9AA induced an inhibition of the kinase activity of cdk2/
cycle E complex (Figure 2), indicating that the HIV-1
infected cell line(s) may be more sensitive to the drug
treatment, as compared to the HIV-1 negative cell line(s).
P21/waf1 has been shown to have pleiotropic functions
that are cell-type specific [51-53]. Most recently, the p21/
waf1 function was identified as a molecular barrier for
HIV infection of stem cells [18]. Zhang J et al have demon-
strated a novel mechanism in which the anti-HIV effect of
p21/waf1 was the result of its interaction with HIV-1 pre-
integration complex (PIC). Therefore, p21/waf1 was sug-
gested to be a possible restriction factor, similar in
function to the TRIM5 and APOBEC3G genes [22-26].
Consistent with this notion we have shown that the inac-
Phosphorylated p53ser15 doesn't interact with HIV-1 Tat pr teinFigure 4
Phosphorylated p53ser15 doesn't interact with HIV-1 
Tat protein. (A) ACH2 cells were transfected with FLAG-
Tat and treated with 9AA or DMSO as a mock control. 
Expression of FLAG-Tat was detected by anti-FLAG (Sigma). 
Reactivation of p53ser15 was evaluated by anti-p53ser15 
(Cell Signaling). (B) The cell lysates were then used for immu-
noprecipitation with anti-p53 or anti-p53ser15 (Cell Signal-
ing). The immunopreciptated complexes were separated on 
4–20% SDS-PAGE gels and then submitted to western blot 
to detect the presence of FLAG-Tat.
Table 1: Viral mRNA levels present in CEMs under different treatments
Treatment mRNA level (24 hrs) mRNA level (48 hrs) mRNA level (72 hrs)
HIV-1+DMSO 35.8 63.4 340.3
HIV-1+ 9AA 21.7 16.2 21.7
CEM cells were infected with HIV-1 for 6 hrs before treatments with DMSO/or drug 9AA. The CEMs with different treatments were harvested at 
three time points: 24, 48 and 72 hrs, respectively. Viral mRNA levels were analyzed by qPCR.Page 6 of 9
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infection can be restored by a small molecule 9AA. Fur-
ther, the 9AA-induced p21/waf1 was found to be recruited
to HIV-1 PIC. Interestingly, we found the small molecule
9AA also inhibits the viral DNA integration step, which
indicates that the drug 9AA is involved in the late stage of
HIV-1 infection, rather than the early stages of infection.
Conclusion
In our current study, we have shown for the first time a
functional restoration of the important signaling path-
way(s) inactivated by HIV-1 infection using small chemi-
cal molecules. Further, our study also revealed a
molecular mechanism by which the 9AA-induced inhibi-
tion of HIV-1 virus replication. It would be of great inter-
est to carry out a future screening of a large number of
chemically synthesized 9AA analogs, through which we
may be able to identify more effective components in acti-
vating the p53 and p21/waf1 pathways, and in inhibiting
virus replication at low concentrations. Therefore our
results may provide a novel therapeutical arsenal for com-
bating HIV-1 infection.
Materials and methods
Plasmids, drugs and antibodies
Flag-Tat plasmid was obtained from Dr. Hiscott J.
(McGill, Montreal). Drug 9-aminoacridine (9-AA) and
DMSO was purchased from Sigma (Cata.Nr. 06650). P44
peptide was synthesized from GenScript Corporation
(Piscataway, USA). Anti-p53 and anti-p53ser15 were pur-
chased from Cell Signaling; anti-FLAG was purchased
from Sigma; anti-p21/waf1 and anti-Actin were purchased
from Santa Cruz Inc.
Cell culture, transfections and drug treatments
ACH2, CEM and PBMC cells were maintained in RPMI-
1640 medium supplemented with 10% FBS, L-glutamine
(2 mM), and penicillin (100 U/ml)/streptomycin (100
µg/ml) (Quality Biological). For transfection of FLAG-Tat
plasmids into ACH2 cells, five millions ACH2 cells were
transfected with 5 µg of plasmid by nucleofection accord-
ing to the manufacturer's protocol (Amaxa, Cologne, Ger-
many). The cells were then incubated for 6 hrs before
treatment with 9AA or DMSO as mock control. Twenty
four hrs after drug or DMSO treatment, the cells were har-
vested for evaluation of the Tat expression and IP experi-
ments with specific antibodies.
Cell viability assays
After the indicated time of drug treatment, the cells were
harvested and stained by Trypan blue. The viable cell
number was normalized with control group and the
results were expressed as relative cell viability. To evaluate
the effects of 9AA on long-term growth, we collected
PHA+IL-2 activated PBMC cells at different time-points, 0,
6, 12 and 18 days and stained for viability.
Co-immunprecipitations
Cells were harvested at 4°C and cell pellets were washed
with Dulbecco's phosphate-buffered saline (PBS). Cell
lysates were prepared as previously described [18]. Five
micrograms of Anti-MA (ABI Inc., Columbia, MD) were
incubated with 2 mg of whole cell lysates overnight at 4°C
with rotation. The overnight-incubated mixture was then
cleared by centrifugation and Protein A/G beads (30%
slurry) were added for 2 h at 4°C. The immunoprecipi-
tated complex was washed with buffer K (150 mM KCl, 20
mM HEPES, pH 7.4, 5 mM MgCl2), then resuspended in
SDS-PAGE loading laemmli buffer. Samples were sepa-
rated on a 4–20% SDS/PAGE gel and subjected to western
blot.
Western blotting analysis
For SDS-PAGE and western blotting of p53, p21/waf1 and
Tat, total cellular proteins were prepared with ice-cold
lysis buffer (50 mM Tris, 5 mM EDTA, 0.1% Triton X-100,
150 mM NaCl and mixed cocktail protease inhibitors).
Cell debris was removed by centrifugation, the superna-
P21/waf1 is recruited to HIV-1 preintegration complex (PIC)Figure 5
P21/waf1 is recruited to HIV-1 preintegration com-
plex (PIC). ACH2 cells were treated with 9AA or DMSO 
as mock control. Cells were then harvested, lysed and sub-
mitted to immunoprecipitation with anti-MA or anti-RT (ABI 
Inc., Columbia, MD). The immunopreciptated complexes 
were separated on 4–20% SDS-PAGE gels and then submit-
ted to western blot to detect the presence p21/waf1. P21/
waf1 is found to be present in the anti-MA immunoprecipita-
tion complex.Page 7 of 9
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determined by protein quantification kit (Bio-Rad, CA).
Protein samples were separated on 4–20% Tris-glycine
gels (Invitrgen), and transferred on PVDF membranes.
Anti-p53, anti-p53ser15 (Cell Signaling) and anti-p21/
waf1 were used for immunodetection (Santa Cruz).
RT Assays
Reverse transcriptase assay was performed according to a
standard procedure. In brief, 10 ul of cell free supernatant
was incubated in RT buffer (0.2 M Tris-HCL, 0.2 M DTT,
0.2 M MgCl2, 0.2 M KCL) in the presence of 0.1% Triton
X-100, PolyA template, PolyD(T) primer and 3HTTP over-
night at 37°C. After incubation 5 ul of the reaction mix
was spotted on a DEAE filter and allowed to dry. Excess
3HTTP was removed by four washes with 5% Na2HPO4
followed by rinsing with water. Incorporation of 3HTTP
was measured using a scintillation counter. RT activity is
measured as CPM according to the scintillation readout.
Quantitative real-time PCR
CEM (12D7) cells were infected with HIV-1 LAI and fol-
lowed by 9AA or DMSO treatments. Cells were harvested
at different time-points, 24, 48, 72 hrs. Total DNA was iso-
lated by DNAzol® Genomic DNA Isolation Reagent
according to their instruction, and analyzed by Real-Time
PCR using the TaqMan method with primers and probes
specific for late reverse transcripts. Products were ampli-
fied from 10 µl of DNA in 50 µl reactions containing 1 ×
TaqMan Universal PCR Master Mix, 300 nM primers and
100 nM probe with primers: FOR-LATE (5'-TGTGT-
GCCCGTCTGTTGTGT-3'), REV-LATE (5'-GAGTCCT-
GCGTCGAGAGAGC-3') and the probe (5'-/56-FAM/
CAGTGGCGCCCGAACAGGGA/36-TAMTph/-3) (Inte-
grated DNA Technologies, Inc).
Kinase Assays
ACH2 cells treated with 9AA or DMSO were harvested in
vitro kinase assay. Kinase assay was performed after
immunoprecipitatting with anti-cycle E ab from 2 mg of
ACH2 or CEM cells treated with 9AA or DMSO as mock
control. The kinase assay was performed according to
method described previously [54]. Phosphorylated sub-
strate Histone H1 was resolved on 4–20% Tris-glycine gel,
dried and then subjected to autoradiography (Packard
Instruments, Wellesley, MA).
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